These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

854 related articles for article (PubMed ID: 32201163)

  • 1. Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2
    Hu Y; Wang S; Ding N; Li N; Huang J; Xiao Z
    Clin Breast Cancer; 2020 Aug; 20(4):e403-e409. PubMed ID: 32201163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio in Different Phenotypes of Locally Advanced Breast Cancer During Neoadjuvant Systemic Treatment.
    Muñoz-Montaño W; Cabrera-Galeana P; Alvarado-Miranda A; Villarreal-Garza C; Mohar A; Olvera A; Bargallo-Rocha E; Lara-Medina F; Arrieta O
    Clin Breast Cancer; 2020 Aug; 20(4):307-316.e1. PubMed ID: 32305297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?
    Ulas A; Avci N; Kos T; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
    J BUON; 2015; 20(3):714-22. PubMed ID: 26214622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and Predictive Impact of Beta-2 Adrenergic Receptor Expression in HER2-Positive Breast Cancer.
    Caparica R; Richard F; Brandão M; Awada A; Sotiriou C; de Azambuja E
    Clin Breast Cancer; 2020 Jun; 20(3):262-273.e7. PubMed ID: 32229175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio with ER and PR in breast cancer patients and their changes after neoadjuvant chemotherapy.
    Xu J; Ni C; Ma C; Zhang L; Jing X; Li C; Liu Y; Qu X
    Clin Transl Oncol; 2017 Aug; 19(8):989-996. PubMed ID: 28247194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
    Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
    J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2-Directed Chemotherapy in HER2-Positive Breast Cancer.
    Meisel JL; Zhao J; Suo A; Zhang C; Wei Z; Taylor C; Aneja R; Krishnamurti U; Li Z; Nahta R; O'Regan R; Li X
    Clin Breast Cancer; 2020 Feb; 20(1):19-24. PubMed ID: 31806448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of adjuvant chemotherapy in patients with ER + /HER2- breast cancer, assessed by propensity score matching: significance of nuclear grade and nodal status.
    Tanaka N; Hirano A; Hattori A; Ogura K; Kamimura M; Inoue H; Yukawa H; Sakaguchi S; Matsuoka A; Kodera A; Shimizu T
    Breast Cancer; 2021 Jan; 28(1):40-47. PubMed ID: 32592141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of outcomes in inflammatory breast cancer.
    Al Jarroudi O; El Bairi K; Abda N; Zaimi A; Jaouani L; Chibani H; Afqir S
    Biomark Med; 2021 Oct; 15(14):1289-1298. PubMed ID: 34486882
    [No Abstract]   [Full Text] [Related]  

  • 10. Biological Characteristics and Long-term Outcomes in Node-negative Breast Cancer.
    Agostinetto E; Giordano L; Torrisi R; De Sanctis R; Masci G; Losurdo A; Zuradelli M; Tinterri C; Gatzemeier W; Testori A; Alloisio M; De Rose F; Fernandes B; Santoro A
    Clin Breast Cancer; 2020 Aug; 20(4):e481-e489. PubMed ID: 32279915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response and Prognosis of Docetaxel and Cyclophosphamide as Neoadjuvant Chemotherapy in ER
    Hayashi N; Yagata H; Tsugawa K; Kajiura Y; Yoshida A; Takei J; Yamauchi H; Nakamura S
    Clin Breast Cancer; 2020 Dec; 20(6):462-468. PubMed ID: 33046356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients.
    Cantini L; Pistelli M; Merloni F; Fontana A; Bertolini I; De Angelis C; Bastianelli L; Della Mora A; Santinelli A; Savini A; Maccaroni E; Diodati L; Falcone A; Berardi R
    Clin Breast Cancer; 2020 Feb; 20(1):e89-e98. PubMed ID: 31378534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of Platelet-to-Lymphocyte Ratio, Neutrophil-to-Lymphocyte Ratio, and Lymphocyte-to-White Blood Cell Ratio in Colorectal Cancer Patients Who Received Neoadjuvant Chemotherapy.
    Jia W; Yuan L; Ni H; Xu B; Zhao P
    Technol Cancer Res Treat; 2021; 20():15330338211034291. PubMed ID: 34308689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can the Neutrophil to Lymphocyte Ratio Predict Complete Pathologic Response to Neoadjuvant Breast Cancer Treatment? A Systematic Review and Meta-analysis.
    Cullinane C; Creavin B; O'Leary DP; O'Sullivan MJ; Kelly L; Redmond HP; Corrigan MA
    Clin Breast Cancer; 2020 Dec; 20(6):e675-e681. PubMed ID: 32653471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up.
    Lundgren C; Bendahl PO; Ekholm M; Fernö M; Forsare C; Krüger U; Nordenskjöld B; Stål O; Rydén L
    Breast Cancer Res; 2020 Dec; 22(1):140. PubMed ID: 33357231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dynamic change of neutrophil to lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients.
    Dan J; Tan J; Huang J; Zhang X; Guo Y; Huang Y; Yang J
    Breast Cancer; 2020 Sep; 27(5):982-988. PubMed ID: 32306184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients.
    Graziano V; Grassadonia A; Iezzi L; Vici P; Pizzuti L; Barba M; Quinzii A; Camplese A; Di Marino P; Peri M; Veschi S; Alberti S; Gamucci T; Di Gioacchino M; De Tursi M; Natoli C; Tinari N
    Breast; 2019 Apr; 44():33-38. PubMed ID: 30611095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Neutrophil to Lymphocyte Ratio Predicts the Response to Neoadjuvant Chemotherapy in Luminal B Breast Cancer.
    Rivas M; Acevedo F; Dominguez F; Galindo H; Camus M; Oddo D; Villarroel A; Razmilic D; Peña J; Munoz Medel M; Navarro ME; Perez-Sepulveda A; Medina L; Merino T; Briones J; Kalergis A; Sanchez C
    Asian Pac J Cancer Prev; 2019 Jul; 20(7):2209-2212. PubMed ID: 31350986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: An updated meta-analysis of 17079 individuals.
    Guo W; Lu X; Liu Q; Zhang T; Li P; Qiao W; Deng M
    Cancer Med; 2019 Aug; 8(9):4135-4148. PubMed ID: 31197958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer.
    Vargo JA; Beriwal S; Ahrendt GM; Soran A; Johnson RR; McGuire K; Bhargava R
    Oncology; 2011; 80(5-6):341-9. PubMed ID: 21791944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.